ItalyA study published in 'The BMJ' has identified hair loss (alopecia) as a potential side effect of GLP-1 agonist drugs like Ozempic, which are used to treat type 2 diabetes and obesity. Researchers compared the rates of alopecia among adults with type 2 diabetes using GLP-1 agonists versus other diabetes medications such as SGLT-2 inhibitors and DPP-4 inhibitors. The findings suggest that GLP-1 agonists are associated with a significantly higher risk of non-scarring alopecia—where hair follicles remain intact and hair can regrow—compared to the other drug classes. Specifically, the risk was 53% higher than with SGLT-2 inhibitors and 72% higher than with DPP-4 inhibitors. The researchers note that rapid weight loss, a known trigger for hair loss, may contribute to this effect, along with possible deficiencies in iron or zinc and hormonal changes.
Bias read (Center): The article presents a medical study on the side effects of a class of drugs used for diabetes and obesity. It provides balanced information by citing research findings, comparing different drug types, and noting areas where further study is needed. There is no evident ideological framing or bias in
